Becton, Dickinson and Company

(New York Stock Exchange)

Top News rankings and signal summaries are processed using AI and may contain errors.

21
Somewhat Bearish -25

Becton, Dickinson and Company $BDX Shares Sold by AMI Asset Management ...

AI-generated analysis

AMI Asset Management Corp reduced its stake in Becton, Dickinson and Company (BDX) by 2.4% during the first quarter, selling 6,482 shares to hold 263,904 shares valued at $41.49 million. While AMI decreased its position, several other institutional investors including Steph & Co., SHP Wealth...

Bullish Signals

  • Major investors increased or initiated BDX positions in Q4.
  • Barclays raised price target to $204 with overweight rating.
  • Quarterly dividend of $1.05 offers 2.7% yield.

Bearish Signals

  • Weiss Ratings downgraded BDX to 'sell (d+)' rating.
  • Analysts lowered price targets between $159.00 and $175.00.
  • Insiders sold shares totaling over $965,000 recently.
  • High PE ratio of 39.19 and payout over 100%.
22
Bullish +65

Becton, Dickinson And Company (BDX) Stock Analysis: Exploring A 14% ...

AI-generated analysis

Becton, Dickinson and Company (NYSE: BDX) is a global leader in medical instruments and supplies with a market capitalization of $42.96 billion. Headquartered in Franklin Lakes, New Jersey, the company serves healthcare institutions, life science researchers, and the pharmaceutical industry. Currently trading at $155.92, the...

Bullish Signals

  • Potential upside of 14% with analyst target price of $177.75.
  • Forward P/E ratio of 11.64 indicates relative undervaluation.
  • Revenue growth rate of 5.20% sustains financial performance.
  • Robust free cash flow exceeds $4.5 billion.
  • Six buy and eight hold ratings show analyst confidence.
23
Slightly Bullish +15

How Investors Are Reacting To BD Stock After An Earnings Beat

Dividend Earnings report Share buyback AI-generated analysis

Becton Dickinson (BDX) reported a Q4 fiscal 2026 earnings beat with sales of US$5,274m and net income of US$696m. The company raised its quarterly dividend to US$1.06 and authorized repurchases of up to 10 million shares, signaling a strategic focus on capital returns and recurring...

Bullish Signals

  • Q4 earnings beat with sales of US$5,274m and net income of US$696m.
  • Raised quarterly dividend to US$1.06 and authorized 10 million share repurchases.
  • Full-year fiscal 2026 sales reached US$19.5b showing medtech platform resilience.

Bearish Signals

  • Management guided for low single-digit GAAP revenue growth in fiscal 2027.
  • Headwinds include Alaris replacement cycle and weaker China demand.
  • Debt not well covered by operating cash flow.
  • Bard PowerPort litigation could pressure margins and limit capital returns.
  • Analyst fair value estimates suggest potential downside risks.
24
Somewhat Bullish +35

Becton Dickinson (BDX) Surpasses Q4 Earnings and Revenue Estimates

Earnings report AI-generated analysis

Becton Dickinson and Company (BDX) reported fourth-quarter earnings of $4.15 per share, surpassing the Zacks Consensus Estimate of $4.06. This result represents a 2.22% positive surprise compared to analyst expectations, continuing a streak where the company has beaten EPS estimates for four consecutive quarters. Revenue...

Bullish Signals

  • Beat Q4 EPS by $0.09 for fourth consecutive quarter.
  • Revenue hit $5.27B, exceeding forecasts by 2.96%.
  • Holds Zacks Rank #2 Buy rating.

Bearish Signals

  • Revenue dropped from $5.89B to $5.27B.
  • Stock underperformed S&P 500 by 4.5% YTD.
25
Somewhat Bullish +50

Becton Dickinson (BDX) Earnings Expected to Grow: Should You Buy?

Earnings report AI-generated analysis

Becton Dickinson and Company (BDX) is preparing to report quarterly earnings for the period ended September 2026, with results expected on November 5. Analysts anticipate a year-over-year earnings per share increase of 2.5% to $4.06, despite a projected revenue decline of 13% to $5.12 billion....

Bullish Signals

  • Analysts raised estimates, yielding +0.21% Zacks Earnings ESP.
  • Holds Zacks Rank #2 (Buy) for strong predictive power.
  • Beat EPS in 4 of last 5 quarters.